Author

Marie-Claude C. Hofmann

The University of Texas MD Anderson Cancer CenterORCID 0000-0002-4899-8039Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Assay:clinical cohort / trial· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Joseph L. KiddiD· 2 shared Rozita Bagheri‐YarmandiD· 2 shared Aatish Thennavan· 1 shared Ali DadbiniD· 1 shared Anastasios ManiakasiD· 1 shared Andrea Ruiz-JuradoiD· 1 shared CLIFFORD C. STEPHANiD· 1 shared David Avila Ramirez· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Joseph L. KiddORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cells

Jerry H. Houl, Rozita Bagheri‐Yarmand, Muthusamy Kunnimalaiyaan, Paola Miranda Mendez, Joseph L. Kidd, Ali Dadbin, Andrea Ruiz-Jurado, Parag A Parekh, Ying C. Henderson, Nikhil S. Chari, Aatish Thennavan, Reid Trenton Powell, CLIFFORD C. STEPHAN, Xiao Ling Zhao, Anastasios Maniakas, , Marie-Claude C. Hofmann

This study identifies a link between the ETV5/p38 signaling axis and aggressive thyroid cancers, showing that combining p38 inhibitors with BRAF inhibitors improves treatment outcomes.

Molecular Cancer Therapeutics · Dec 2, 2025Peer-reviewedCancer Biology

Activating RET Mutations Promotes Osteoblastic Bone Metastases in Medullary Thyroid Cancer

Rozita Bagheri‐Yarmand, Gabriel M. Pagnotti, Joseph L. Kidd, David Avila Ramirez, Trupti Trivedi, Leah Guerra, Zhongya Wang, Lucia Martinez Cruz, Jade M. Moehle, Yaashmin Shiny Jebaraj, Xinhai Wan, Jian H. Song, Roland L. Bassett, Sue-Hwa Lin, Mimi I-Nan Hu, , Theresa A. Guise

This study shows that activating RET mutations in medullary thyroid cancer (MTC) cells promote osteoblastic bone metastases by increasing osteoprotegerin (OPG), which inhibits bone resorption and is linked to poor patient survival.

bioRxiv · Jul 9, 2025 · PreprintCancer Biology